{"id":799476,"date":"2025-01-10T07:38:01","date_gmt":"2025-01-10T12:38:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\/"},"modified":"2025-01-10T07:38:01","modified_gmt":"2025-01-10T12:38:01","slug":"y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\/","title":{"rendered":"Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, Jan.  10, 2025  (GLOBE NEWSWIRE) &#8212; Y-mAbs Therapeutics, Inc. (the \u201cCompany\u201d or \u201cY-mAbs\u201d) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit.<\/p>\n<p>\u201cI am pleased to welcome Doug to Y-mAbs as the new DANYELZA Business Unit head,\u201d said Michael Rossi, President and Chief Executive Officer. \u201cWe believe Doug\u2019s extensive experience leading pharmaceutical commercialization and operations on a global scale will be instrumental in our continued commercial expansion and growth to unlocking the full potential value of DANYELZA beyond pediatric oncology.\u201d<\/p>\n<p>Mr. Gentilcore brings over two decades of strategic leadership experience in the pharmaceutical industry. Prior to joining Y-mAbs, he served as Chief Commercial Officer and then Chief Executive Officer of ARTMS, Inc., a global leader in the development of novel technologies and products which enable the high-quality and high-yield production of the world\u2019s most-used diagnostic imaging isotopes. Upon the company\u2019s acquisition by Telix Pharmaceuticals, Mr. Gentilcore returned to a full-time role at Implerem, LLC, a commercial pharmaceutical consulting firm he founded in 2019. Prior to ARTMS, Mr. Gentilcore was Vice President of Global Sales and Business Operations at Jubilant Radiopharma, where he led all commercial operations for the company, including the go-to-market strategy for Jubilant DraxImage Radiopharma. Earlier, Mr. Gentilcore held sales roles of increasing responsibility at General Electric\u2019s Healthcare Division in Medical Diagnostics and was a regional commercial leader at Pfizer Pharmaceuticals. He received a B.A. in Business Economics from Randolph-Macon College.<\/p>\n<p align=\"justify\">Sue Smith, Chief Commercial Officer, will be departing the organization. Mr. Rossi commented, \u201cOn behalf of the Board of Directors and the entire Y-mAbs teams, I want to thank Sue for her commitment in leading our U.S. Commercial team and on the relaunch of DANYELZA. Sue has been a valued member of our leadership team, and we wish her all the best in her future endeavors.\u201d<\/p>\n<p>\n        <strong>About DANYELZA\u00ae (naxitamab-gqgk)<\/strong><br \/>\n        <br \/>DANYELZA\u00ae (naxitamab-gqgk) is indicated, in combination with granulocyte-macrophage colony-stimulating factor (&#8220;GM-CSF&#8221;), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. This indication was approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory trial. DANYELZA\u00ae includes a Boxed Warning for serious infusion-related reactions, such as cardiac arrest and anaphylaxis, and neurotoxicity, such as severe neuropathic pain and transverse myelitis. See full Prescribing Information for complete Boxed Warning and other important safety information.<\/p>\n<p>DANYELZA is currently not approved for the treatment of osteosarcoma in any jurisdiction.<\/p>\n<p align=\"justify\">\n        <strong>About Y-mAbs <\/strong><br \/>\n        <br \/>Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company\u2019s technologies include its investigational Self-Assembly DisAssembly (\u201cSADA\u201d) Pretargeted Radioimmunotherapy Platform (\u201cPRIT\u201d) and bispecific antibodies generated using the Y-BiClone platform. The Company\u2019s broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA\u00ae (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about our business model, including financial outlook for 2024 and beyond. Words such as \u2018\u2018anticipate,\u2019\u2019 \u2018\u2018believe,\u2019\u2019 \u201ccontemplate,\u201d \u2018\u2018continue,\u2019\u2019 \u2018\u2018could,\u2019\u2019 \u2018\u2018estimate,\u2019\u2019 \u2018\u2018expect,\u2019\u2019 \u201chope,\u201d \u2018\u2018intend,\u2019\u2019 \u2018\u2018may,\u2019\u2019 \u2018\u2018might,\u2019\u2019 \u2018\u2018plan,\u2019\u2019 \u2018\u2018potential,\u2019\u2019 \u2018\u2018predict,\u2019\u2019 \u2018\u2018project,\u2019\u2019 \u2018\u2018should,\u2019\u2019 \u2018\u2018target,\u2019\u2019 \u201cwill,\u201d \u2018\u2018would\u2019,\u2019 \u201cguidance,\u201d \u201cgoal,\u201d \u201cobjective,\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company\u2019s business is subject to risks and uncertainties affecting the Company including those described in the \u201cRisk Factors\u201d section included in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and the Company\u2019s Quarterly Report on Form 10-Q for the quarterly periods ended March 31, 2024, and September 30, 2024, and future filings and reports by the Company. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.<\/p>\n<p align=\"justify\">SADA\u00ae, SADA PRIT\u00ae, DANYELZA\u00ae and Y-mAbs\u00ae are registered trademarks of Y-mAbs Therapeutics, Inc.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Courtney Dugan<br \/>VP, Head of Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YACss5WH1hk73eOk7WcVNfXQL4QHYQm62M3jSB6tw4EHxShzZTcHjAwPGA-PzkltTqxYJGBrqbIbTN-YhK5_uQ==\" rel=\"nofollow\" target=\"_blank\">cdu@ymabs.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyOTczNSM2Njg3NjY0IzUwMDA1MDgxNw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OGRhNDIwNWEtMjE3My00YTFlLTk2ZmYtNDJlN2E3ZGYxNGIxLTUwMDA1MDgxNw==\/tiny\/Y-mAbs-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) &#8212; Y-mAbs Therapeutics, Inc. (the \u201cCompany\u201d or \u201cY-mAbs\u201d) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit. \u201cI am pleased to welcome Doug to Y-mAbs as the new DANYELZA Business Unit head,\u201d said Michael Rossi, President and Chief Executive Officer. \u201cWe believe Doug\u2019s extensive experience leading pharmaceutical commercialization and operations on a global scale will be instrumental in our continued commercial expansion and growth to unlocking the full potential value of DANYELZA beyond pediatric oncology.\u201d Mr. Gentilcore brings over two decades of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-799476","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) &#8212; Y-mAbs Therapeutics, Inc. (the \u201cCompany\u201d or \u201cY-mAbs\u201d) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit. \u201cI am pleased to welcome Doug to Y-mAbs as the new DANYELZA Business Unit head,\u201d said Michael Rossi, President and Chief Executive Officer. \u201cWe believe Doug\u2019s extensive experience leading pharmaceutical commercialization and operations on a global scale will be instrumental in our continued commercial expansion and growth to unlocking the full potential value of DANYELZA beyond pediatric oncology.\u201d Mr. Gentilcore brings over two decades of &hellip; Continue reading &quot;Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-10T12:38:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyOTczNSM2Njg3NjY0IzUwMDA1MDgxNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit\",\"datePublished\":\"2025-01-10T12:38:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\\\/\"},\"wordCount\":809,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyOTczNSM2Njg3NjY0IzUwMDA1MDgxNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\\\/\",\"name\":\"Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyOTczNSM2Njg3NjY0IzUwMDA1MDgxNw==\",\"datePublished\":\"2025-01-10T12:38:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyOTczNSM2Njg3NjY0IzUwMDA1MDgxNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyOTczNSM2Njg3NjY0IzUwMDA1MDgxNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\/","og_locale":"en_US","og_type":"article","og_title":"Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit - Market Newsdesk","og_description":"NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) &#8212; Y-mAbs Therapeutics, Inc. (the \u201cCompany\u201d or \u201cY-mAbs\u201d) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit. \u201cI am pleased to welcome Doug to Y-mAbs as the new DANYELZA Business Unit head,\u201d said Michael Rossi, President and Chief Executive Officer. \u201cWe believe Doug\u2019s extensive experience leading pharmaceutical commercialization and operations on a global scale will be instrumental in our continued commercial expansion and growth to unlocking the full potential value of DANYELZA beyond pediatric oncology.\u201d Mr. Gentilcore brings over two decades of &hellip; Continue reading \"Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-10T12:38:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyOTczNSM2Njg3NjY0IzUwMDA1MDgxNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit","datePublished":"2025-01-10T12:38:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\/"},"wordCount":809,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyOTczNSM2Njg3NjY0IzUwMDA1MDgxNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\/","name":"Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyOTczNSM2Njg3NjY0IzUwMDA1MDgxNw==","datePublished":"2025-01-10T12:38:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyOTczNSM2Njg3NjY0IzUwMDA1MDgxNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyOTczNSM2Njg3NjY0IzUwMDA1MDgxNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/y-mabs-appoints-experienced-commercial-leader-as-head-of-danyelza-business-unit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/799476","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=799476"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/799476\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=799476"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=799476"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=799476"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}